A humble yet groundbreaking clinical trial at Memorial Sloan Kettering Cancer Center (MSK) has achieved unprecedented results ...

Bradley Monk shares key insights and breakthroughs in gynaecologic oncology from ESGO 2025, shaping cancer care's future.

of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose- >30% cORR difference between belrestotug + dostarlimab vs dostarlimab ...

The drugmaker remains convinced of the potential of the drug, however, and has just reported results of a trial comparing Jemperli (dostarlimab) to Merck & Co's market-leading Keytruda ...

including the start of multiple phase 3 studies of belrestotug in combination with GSK’s PD-1 inhibitor Jemperli (dostarlimab). In GALAXIES, there was a “clinically meaningful” reduction at ...

The researchers found biomarkers of macrophage activity and immune activity were associated with resistance and response to Opdivo plus Cabometyx.

Myeloproliferative disorders (MPDs) are a group of blood cancers traditionally treated using medications, blood filtration, and chemotherapy or radiation. In recent news, several studies and ...